市場調査レポート

商品コード

1806344

前立腺肥大症治療市場：治療タイプ、製品タイプ、エンドユーザー、流通チャネル別-2025-2030年の世界予測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2025-2030

出版日: 2025年08月28日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日

カスタマイズ可能

適宜更新あり

価格

PDF, Excel & 1 Year Online Access (Single User License)

USD 3,939 584,153円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

PDF, Excel & 1 Year Online Access (2-5 User License)

USD 4,249 630,126円

レポートPDF及びExcelを5名までご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

PDF, Excel & 1 Year Online Access (Site License)

USD 5,759 854,059円

レポートPDF及びExcelを、同じ地理上の位置に所在する事業所内に所属の全ての方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

PDF, Excel & 1 Year Online Access (Enterprise User License)

USD 6,969 1,033,502円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.30円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

前立腺肥大症治療市場は、2024年には87億1,000万米ドルとなり、2025年には92億米ドル、CAGR 5.91%で成長し、2030年には123億米ドルに達すると予測されています。

主な市場の統計
基準年2024	87億1,000万米ドル
推定年2025	92億米ドル
予測年2030	123億米ドル
CAGR（%）	5.91%

次世代の前立腺肥大症治療パラダイムを定義する新たな臨床開発と市場促進要因を探る

前立腺肥大症（BPH）は、高齢化した男性人口における高い有病率と、QOLへの深刻な影響から、臨床的に重要な領域として浮上しています。高齢患者層への人口統計学的シフトが加速するにつれ、世界中のヘルスケアシステムは、安全で効果的かつコスト効率の高い治療を提供しなければならないというプレッシャーに直面しています。近年、臨床的革新、患者の嗜好、進化する償還経路の相互作用により、前立腺肥大症に伴う中等度から重度の下部尿路症状に対する治療目標が部分的に再定義されています。

前立腺肥大症管理における治療方法と患者の転帰を形成する基本的な技術的・規制的変革の特定

前立腺肥大症治療の情勢は、技術の飛躍的進歩と規制の枠組みの変化により、大きな変貌を遂げつつあります。歴史的に薬物療法と経尿道的切除手術に大きく依存してきたこの分野は、現在、最先端のエネルギーベースの治療法、画像誘導介入、標的塞栓療法の台頭を目の当たりにしています。これらの技術革新は、今日の患者コホートにとって重要な優先事項である排尿機能と性機能を維持しながら、手術による罹患率を最小限に抑えることを目的としています。

米国の関税調整が治療アクセスサプライチェーンと前立腺肥大症治療の革新経路に及ぼす収束効果の分析

2025年に発表された米国の関税調整は、世界のサプライチェーンに波及効果をもたらし、前立腺肥大症治療の主要コンポーネントのコスト構造とアクセス性に影響を及ぼしています。カテーテルやレゼクトスコープから泌尿器科用レーザーやインプラントに至るまで、多くの医療機器は海外で製造された部品を起源とするか、または組み込まれています。輸入関税が上昇するにつれ、流通業者やヘルスケアプロバイダーは調達費用の増加に直面し、ひいては価格交渉や償還の議論に影響を及ぼすことになります。

前立腺肥大症管理へのアプローチを形成する、きめ細かな治療タイプ製品エンドユーザーと流通チャネルのセグメンテーション洞察の解明

市場セグメンテーションの微妙な理解により、戦略的投資と製品開拓のための重要な変曲点が明らかになります。治療の種類を考慮すると、薬物療法が引き続き基本的な重要性を占めており、5αリダクターゼ阻害薬とα遮断薬が薬理学的介入の第一選択薬となっています。しかし、前立腺動脈塞栓術や水蒸気療法を含む低侵襲治療分野は、回復時間の短縮と良好な安全性プロファイルにより急速に支持を集めています。同時に、外科治療も従来の経尿道的前立腺切除術にとどまらず、レーザー手術、前立腺尿道リフト、最小限の組織破壊を優先する経尿道的切開法など、多様化しています。

標的前立腺肥大症治療戦略の参考となる、アメリカ大陸欧州中東アフリカおよびアジア太平洋における地理的市場変動の評価

前立腺肥大症治療のエコシステムを形成する上で、地域ダイナミクスは極めて重要な役割を担っており、それぞれの地域が独自の規制、臨床、経済的考察を行っています。南北アメリカでは、広範な臨床試験ネットワークと確立された支払者と医療提供者の協力関係に支えられ、強固な償還の枠組みと早期の技術導入が、デバイスベースの治療と先進的な薬物療法の急速な統合を促進しています。

革新的戦略のハイライトパートナーシップ前立腺肥大症治療における主要バイオ医薬品デバイス技術企業の競合ダイナミクス

前立腺肥大症領域における競合勢力は、定評ある製薬企業と革新的なデバイスメーカーの融合によって定義されています。大手医薬品メーカーは、5αリダクターゼ阻害剤とα遮断剤における数十年にわたるポートフォリオの経験を活用する一方、隣接するバイオ医薬品メーカーは、症状緩和と組織リモデリングの両方に対処する新規の併用療法を模索しています。

前立腺肥大症治療における臨床効果の市場浸透と患者採用を強化するための実行可能な戦略的提言の策定

前向きな業界リーダーは、進化する前立腺肥大症市場で競争優位性を維持するために、多面的なアプローチを優先すべきです。第一に、次世代の低侵襲技術、特に外来またはオフィスベースのアプリケーションに投資することで、回復時間の短縮と生活の質の維持を求める患者の要望に応えることができます。主要なオピニオンリーダーや症例数の多いセンターと協力的なパイロットプログラムを確立することで、導入曲線を加速させ、償還交渉をサポートする説得力のある現実のエビデンスを生み出すことができます。

前立腺肥大症市場評価における調査結果の頑健性を保証する厳密なデータ収集分析および検証プロトコルの詳細

本調査では、包括的な2次調査と的を絞った1次インタビューおよびデータの三角測量とを組み合わせた厳密な手法を採用しました。まず、治療法、デバイスのイノベーション、および政策展開の強固なベースラインを構築するために、査読付きジャーナル、規制データベース、特許出願、および業界のホワイトペーパーを体系的に分析しました。主要な市場シフトのタイミングと範囲を特定するために、過去の規制当局による承認とガイドラインの改訂をマッピングしました。

前立腺肥大症治療領域における将来の方向性と機会を明らかにするための主要知見と戦略的含意の統合

主要な調査結果をまとめると、市場は大きな転換期にあることがわかる。低侵襲治療法の進歩、薬事規制の調整、関税を考慮したサプライチェーンの強化が、治療アルゴリズムと競合力学を再構築しています。セグメンテーション分析では、非外科的介入と特殊製品カテゴリーの重要性が高まっていることが強調され、地域別の洞察では、南北アメリカ、欧州、中東・アフリカ、アジア太平洋地域における市場参入戦略の必要性が強調されています。

低侵襲治療に対する患者の需要により、経尿道的水蒸気アブレーションの採用が増加している
遠隔症状モニタリングと個別化されたBPH投薬管理を可能にする遠隔医療プラットフォームの成長
副作用プロファイルの改善を目的とした選択的5α還元酵素阻害剤の開発が急増
オフィスでの前立腺尿道リフト手術の拡大により、運用コストが削減され、回復時間が改善されます。
BPH進行の早期発見とリスク分類のための人工知能診断ツールの統合
BPH治療および介入に対する価値に基づく償還に影響を与えるリアルワールドエビデンス研究の増加
排尿症状の緩和を強化するためにβ3作動薬とα遮断薬を組み合わせた併用療法の出現
BPH患者の治療結果を最適化するために、薬理ゲノムプロファイリングに基づいた個別投与プロトコル

第6章市場洞察

ポーターのファイブフォース分析
PESTEL分析

第7章米国の関税の累積的な影響2025

第8章前立腺肥大症治療市場：治療タイプ別

医薬品
- 5α還元酵素阻害剤
- アルファ遮断薬
低侵襲治療
- 前立腺動脈塞栓術
- 水蒸気療法
外科的治療
- レーザー手術
- 前立腺尿道リフト
- 経尿道的前立腺切開術
- 経尿道的前立腺切除術

第9章前立腺肥大症治療市場：製品タイプ別

カテーテル
電極
インプラント
前立腺ステント
切除鏡
泌尿器科レーザー

第10章前立腺肥大症治療市場：エンドユーザー別

外来手術センター
クリニック
ホームケア
病院

第11章前立腺肥大症治療市場：流通チャネル別

オフライン
オンライン

第12章南北アメリカの前立腺肥大症治療市場

米国
カナダ
メキシコ
ブラジル
アルゼンチン

第13章欧州・中東・アフリカの前立腺肥大症治療市場

英国
ドイツ
フランス
ロシア
イタリア
スペイン
アラブ首長国連邦
サウジアラビア
南アフリカ
デンマーク
オランダ
カタール
フィンランド
スウェーデン
ナイジェリア
エジプト
トルコ
イスラエル
ノルウェー
ポーランド
スイス

第14章アジア太平洋地域の前立腺肥大症治療市場

中国
インド
日本
オーストラリア
韓国
インドネシア
タイ
フィリピン
マレーシア
シンガポール
ベトナム
台湾

第15章競合情勢

市場シェア分析, 2024
FPNVポジショニングマトリックス, 2024
競合分析
- AbbVie Inc.
- Alembic Pharmaceuticals Limited
- Asahi Kasei Corporation
- Astellas Pharma Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Boston Scientific Corporation
- Cipla Ltd.
- Coloplast Group
- Dr. Reddy's Laboratories
- Eli Lilly and Company
- Endo International PLC
- GlaxoSmithKline plc
- Hikma Pharmaceuticals PLC
- IPG Photonics Corporation
- Lumenis Ltd.
- Olympus Corporation
- Organon group of companies
- PROCEPT BioRobotics Corporation
- ProstaLund AB
- Quanta System
- Richard Wolf GmbH
- Teleflex Incorporated
- Urologix, LLC.

第16章リサーチAI

第17章リサーチ統計

第18章リサーチコンタクト

第19章リサーチ記事

第20章付録

図表

LIST OF FIGURES

FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHAI
FIGURE 24. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 25. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 26. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 104. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 105. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 106. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 107. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 108. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 109. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 120. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 121. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 188. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 190. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 191. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 192. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 193. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 194. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 195. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 196. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 197. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 202. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 203. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 204. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 205. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 206. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 207. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 208. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 209. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 230. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 231. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 232. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 233. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 234. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 235. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 236. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 237. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 244. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 245. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 246. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 247. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 248. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 249. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 250. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 251. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATME

Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 8.71 billion in 2024 and is projected to grow to USD 9.20 billion in 2025, with a CAGR of 5.91%, reaching USD 12.30 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 8.71 billion
Estimated Year [2025]	USD 9.20 billion
Forecast Year [2030]	USD 12.30 billion
CAGR (%)	5.91%

Exploring the Emerging Clinical Developments and Market Drivers Defining the Next Generation of Benign Prostatic Hyperplasia Treatment Paradigms

Benign prostatic hyperplasia (BPH) has emerged as a critical area of clinical focus due to its high prevalence among aging male populations and its profound impact on quality of life. As the demographic shift towards an older patient base accelerates, healthcare systems worldwide face mounting pressure to deliver safe, effective, and cost-efficient interventions. In recent years, the interplay of clinical innovation, patient preference, and evolving reimbursement pathways has partially redefined treatment objectives for moderate to severe lower urinary tract symptoms associated with prostatic enlargement.

The clinical pipeline now features an expanding array of pharmacotherapies aimed at both symptom relief and underlying disease modification. Novel agents targeting androgen pathways, inflammatory mediators, and smooth muscle tone within the prostate are under active investigation. Concurrently, minimally invasive technologies have transitioned from niche options to mainstream considerations, offering shorter recovery times and preserved sexual function relative to traditional surgical approaches. Moreover, professional guidelines have begun to integrate these advancements, urging a more personalized treatment algorithm based on symptom severity, prostate volume, and patient comorbidities.

Consequently, stakeholders across the public and private sectors are aligning around a paradigm that balances clinical efficacy with patient-centric factors such as procedure durability, side effect profiles, and access to care. This introduction sets the stage for an in-depth exploration of how recent clinical developments and market drivers converge to define the next generation of BPH treatment paradigms.

Identifying the Fundamental Technological and Regulatory Transformations Reshaping Treatment Modalities and Patient Outcomes in Prostatic Enlargement Management

The landscape of benign prostatic hyperplasia treatment is undergoing profound transformation driven by both technological breakthroughs and shifting regulatory frameworks. Historically dominated by heavy reliance on pharmacotherapy and transurethral resection surgery, the field now witnesses the rise of cutting-edge energy-based modalities, image-guided interventions, and targeted embolic therapies. These innovations aim to minimize procedural morbidity while preserving urinary and sexual function, key priorities for today's patient cohorts.

On the regulatory front, health authorities have begun to streamline pathways for minimally invasive medical devices and combination regimens, reflecting an increased willingness to consider surrogate endpoints and patient-reported outcomes. Harmonization efforts across major markets are reducing approval timelines for technologies that demonstrate safety and performance in robust clinical studies. Furthermore, the integration of real-world evidence into post-market surveillance has accelerated iterative improvements, enabling manufacturers to refine device designs and procedural techniques at an unprecedented pace.

As a result, treatment modalities once considered experimental are gaining momentum in routine practice. The convergence of technology, regulation, and patient-centered care is reshaping the fundamental approach to prostatic enlargement management. This section delves into these transformative forces, highlighting how they coalesce to create new opportunities for improved patient outcomes and streamlined clinical pathways.

Analyzing the Converging Effects of United States Tariff Adjustments on Treatment Access Supply Chains and Innovation Paths for Prostatic Hyperplasia Care

United States tariff adjustments announced in 2025 have generated ripple effects across global supply chains, impacting the cost structures and accessibility of key benign prostatic hyperplasia treatment components. Many medical devices-ranging from catheters and resectoscopes to urology lasers and implants-originate from or incorporate parts manufactured abroad. As import duties rise, distributors and healthcare providers confront increased procurement expenses, which in turn influence pricing negotiations and reimbursement discussions.

Manufacturers have responded by reassessing their production footprints, exploring near-sourcing strategies, and renegotiating supplier contracts to mitigate steep cost escalations. Simultaneously, emerging trade agreements and tariff exemptions for certain medical goods have provided limited relief, though administrative burdens remain substantial. Consequently, device innovators must balance the imperative to maintain margins with the need to ensure equitable patient access, particularly in outpatient and ambulatory surgical center settings.

Looking ahead, the tariff environment is likely to catalyze broader supply chain resilience measures within the industry. Strategic collaborations and investment in localized manufacturing are expected to gain prominence as companies seek to insulate their operations from future policy shifts. This analysis examines how recent tariff modifications are redefining procurement, distribution, and innovation pathways for prostatic hyperplasia care.

Uncovering Granular Treatment Type Product End User and Distribution Channel Segmentation Insights Shaping Approaches to Prostatic Hyperplasia Management

A nuanced understanding of market segmentation reveals critical inflection points for strategic investment and product development. When treatment type is considered, medications continue to hold foundational importance, with 5-alpha-reductase inhibitors and alpha blockers serving as first-line pharmacologic interventions. Yet the minimally invasive therapy segment, encompassing prostate artery embolization and water vapor therapy, is rapidly gaining traction due to shorter recovery times and favorable safety profiles. At the same time, surgical treatments have diversified beyond traditional transurethral resection of the prostate, now including laser surgery, prostatic urethral lift, and transurethral incision techniques that prioritize minimal tissue disruption.

Examining product type segmentation highlights the essential role of supporting technologies. Catheters, electrodes, and resectoscopes remain indispensable for interventional procedures, while prostatic stents and specialized urology lasers are becoming increasingly sophisticated in their design and application. Each category presents distinct development pathways, driven by evolving clinical requirements and user feedback from surgeons and interventional radiologists.

End-user analysis further clarifies market dynamics, as ambulatory surgical centers gain preference for office-based procedures while hospitals maintain their position in complex surgical cases. Clinics offering pharmacotherapy and minimally invasive office procedures are expanding service portfolios, and homecare models for medication management and post-procedure monitoring are on the rise. Finally, distribution channel trends underscore a transition from traditional hospital procurement networks toward integrated online platforms that streamline ordering, enable real-time inventory management, and support remote training modules for new devices.

Evaluating Geographic Market Variations Across Americas Europe Middle East Africa and Asia Pacific to Inform Targeted Prostatic Hyperplasia Treatment Strategies

Regional dynamics play a pivotal role in shaping the benign prostatic hyperplasia treatment ecosystem, with each geography presenting unique regulatory, clinical, and economic considerations. In the Americas, robust reimbursement frameworks and early technology adoption drive rapid integration of both device-based therapies and advanced pharmacologics, supported by extensive clinical trial networks and established payer-provider collaborations.

In Europe, Middle East & Africa, diverse healthcare infrastructures foster a dual focus on cost containment and equitable access. Regulatory harmonization across the European Union facilitates cross-border device approvals, while emerging markets in the Middle East and Africa prioritize capacity building for minimally invasive techniques, often through international partnerships and training programs.

Across the Asia-Pacific region, accelerating population aging and growing awareness of male health issues are creating a surge in demand for both first-line medications and new procedural options. Governments are increasingly incentivizing local manufacturing and public-private research collaborations to expand access in less penetrated markets. Consequently, regional strategies must be tailored to navigate variations in clinical practice, reimbursement policies, and patient expectations across these diverse territories.

Highlighting Innovative Strategies Partnerships Competitive Dynamics Among Leading Biopharmaceutical Device Technology Companies in Prostatic Hyperplasia Care

Competitive dynamics in the benign prostatic hyperplasia arena are defined by a blend of established pharmaceutical firms and innovative device manufacturers. Leading drug makers leverage decades of portfolio experience in 5-alpha-reductase inhibitors and alpha blockers, while adjacent biopharma players explore novel combination therapies that address both symptom relief and tissue remodeling.

On the device side, global medical technology organizations continue to refine energy-based platforms, offering improved precision and reduced procedural times. Strategic partnerships between device innovators and contract research organizations have accelerated clinical validation, helping to secure favorable regulatory designations. At the same time, emerging companies specialize in niche delivery systems such as water vapor and embolic therapies, carving out competitive positions through targeted clinical data and differentiated user experiences.

The convergence of digital health and urology has also given rise to integrated software solutions that support pre-procedure planning, remote follow-up, and patient-reported outcome tracking. Consequently, the competitive field extends beyond core product offerings to encompass service ecosystems and data analytics capabilities that enhance long-term value for providers and patients alike.

Formulating Actionable Strategic Recommendations to Enhance Clinical Effectiveness Market Penetration and Patient Adoption in Prostatic Hyperplasia Treatment

Forward-looking industry leaders should prioritize a multifaceted approach to maintain competitive advantage in the evolving benign prostatic hyperplasia market. First, investing in next-generation minimally invasive technologies-particularly those with outpatient or office-based application-will address patient demand for reduced recovery times and preserved quality of life. Establishing collaborative pilot programs with key opinion leaders and high-volume centers can accelerate adoption curves and generate compelling real-world evidence to support reimbursement negotiations.

Second, strengthening supply chain resilience through diversified sourcing and near-shoring initiatives will mitigate the financial impacts of evolving trade policies. Engaging in joint ventures with regional manufacturing partners can also facilitate market entry in underpenetrated territories. Third, integrating digital health tools into pre- and post-treatment pathways will enhance patient engagement and enable remote monitoring of outcomes, providing a richer data set for both clinical optimization and payer discussions.

Finally, customizing market access strategies to regional regulatory nuances-such as expedited device review programs in the Americas or harmonized EU approval processes-will streamline time to market. By synchronizing clinical development plans with local policy frameworks and reimbursement landscapes, companies can secure favorable positioning and drive sustainable growth across multiple geographies.

Detailing Rigorous Data Collection Analysis and Validation Protocols Ensuring Robustness of Research Findings in Prostatic Hyperplasia Market Assessment

This research employed a rigorous methodology combining comprehensive secondary research with targeted primary interviews and data triangulation. Initially, peer-reviewed journals, regulatory databases, patent filings, and industry white papers were systematically analyzed to construct a robust baseline of therapeutic modalities, device innovations, and policy developments. Historical regulatory approvals and guideline revisions were mapped to identify timing and scope of major market shifts.

Complementing the desk research, structured interviews with leading urologists, interventional radiologists, procurement specialists, and payers provided firsthand insights into clinical preferences, procedural workflows, and reimbursement challenges. Quantitative data points were validated through cross-referencing publicly available clinical trial registries and device approval summaries, ensuring consistency across multiple sources.

Finally, an iterative review process engaged subject matter experts to refine assumptions, resolve discrepancies, and contextualize findings within broader healthcare trends. This layered approach-incorporating secondary evidence, expert validation, and market feedback-underpins the reliability and depth of the strategic insights presented throughout this report.

Synthesizing Key Findings and Strategic Implications to Illuminate Future Directions and Opportunities in the Benign Prostatic Hyperplasia Treatment Arena

Bringing together the key findings reveals a market at the cusp of significant transition. Advances in minimally invasive therapies, alignment of regulatory pathways, and heightened tariff-driven supply chain considerations are collectively reshaping treatment algorithms and competitive dynamics. Segmentation analysis underscores the growing importance of non-surgical interventions and specialized product categories, while regional insights highlight the need for tailored market access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

The interplay between established pharmaceutical agents and next-generation device platforms points to an integrated future in which combination therapies and digital health solutions drive patient-centered care. For stakeholders eager to navigate this complex ecosystem, the ability to anticipate policy shifts, forge strategic partnerships, and invest in differentiated technologies will determine long-term success. By synthesizing clinical innovation, operational resilience, and market intelligence, industry participants can capture emerging opportunities and deliver impactful outcomes for the growing BPH patient population.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

5.1. Increasing adoption of transurethral water vapor ablation driven by patient demand for minimally invasive care
5.2. Growth in telehealth platforms enabling remote symptom monitoring and personalized BPH medication management
5.3. Surge in development of selective five-alpha reductase inhibitors targeting improved side effect profiles
5.4. Expansion of office-based prostatic urethral lift procedures reducing operational costs and improving recovery times
5.5. Integration of artificial intelligence diagnostic tools for early detection and risk stratification of BPH progression
5.6. Rising real-world evidence studies influencing value-based reimbursement for BPH therapies and interventions
5.7. Emergence of combination therapies pairing beta-3 agonists with alpha-blockers to enhance urinary symptom relief
5.8. Personalized dosing protocols informed by pharmacogenomic profiling to optimize treatment outcomes in BPH patients

6. Market Insights

6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

8.1. Introduction
8.2. Medications
- 8.2.1. 5-Alpha-Reductase Inhibitors
- 8.2.2. Alpha Blockers
8.3. Minimally Invasive Therapies
- 8.3.1. Prostate Artery Embolization
- 8.3.2. Water Vapour Therapy
8.4. Surgical Treatments
- 8.4.1. Laser Surgery
- 8.4.2. Prostatic Urethral Lift
- 8.4.3. Transurethral Incision Of The Prostate
- 8.4.4. Transurethral Resection Of The Prostate

9. Benign Prostatic Hyperplasia Treatment Market, by Product Type

9.1. Introduction
9.2. Catheters
9.3. Electrodes
9.4. Implants
9.5. Prostatic Stents
9.6. Resectoscopes
9.7. Urology Laser

10. Benign Prostatic Hyperplasia Treatment Market, by End User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.4. Homecare
10.5. Hospitals

11. Benign Prostatic Hyperplasia Treatment Market, by Distribution Channel

11.1. Introduction
11.2. Offline
11.3. Online

12. Americas Benign Prostatic Hyperplasia Treatment Market

12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina

13. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland

14. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan

15. Competitive Landscape

15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
- 15.3.1. AbbVie Inc.
- 15.3.2. Alembic Pharmaceuticals Limited
- 15.3.3. Asahi Kasei Corporation
- 15.3.4. Astellas Pharma Inc.
- 15.3.5. Bayer AG
- 15.3.6. Boehringer Ingelheim GmbH
- 15.3.7. Boston Scientific Corporation
- 15.3.8. Cipla Ltd.
- 15.3.9. Coloplast Group
- 15.3.10. Dr. Reddy's Laboratories
- 15.3.11. Eli Lilly and Company
- 15.3.12. Endo International PLC
- 15.3.13. GlaxoSmithKline plc
- 15.3.14. Hikma Pharmaceuticals PLC
- 15.3.15. IPG Photonics Corporation
- 15.3.16. Lumenis Ltd.
- 15.3.17. Olympus Corporation
- 15.3.18. Organon group of companies
- 15.3.19. PROCEPT BioRobotics Corporation
- 15.3.20. ProstaLund AB
- 15.3.21. Quanta System
- 15.3.22. Richard Wolf GmbH
- 15.3.23. Teleflex Incorporated
- 15.3.24. Urologix, LLC.

前立腺肥大症治療市場：治療タイプ、製品タイプ、エンドユーザー、流通チャネル別-2025-2030年の世界予測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2025-2030

次世代の前立腺肥大症治療パラダイムを定義する新たな臨床開発と市場促進要因を探る

前立腺肥大症管理における治療方法と患者の転帰を形成する基本的な技術的・規制的変革の特定

米国の関税調整が治療アクセスサプライチェーンと前立腺肥大症治療の革新経路に及ぼす収束効果の分析

前立腺肥大症管理へのアプローチを形成する、きめ細かな治療タイプ製品エンドユーザーと流通チャネルのセグメンテーション洞察の解明

標的前立腺肥大症治療戦略の参考となる、アメリカ大陸欧州中東アフリカおよびアジア太平洋における地理的市場変動の評価

革新的戦略のハイライトパートナーシップ前立腺肥大症治療における主要バイオ医薬品デバイス技術企業の競合ダイナミクス

前立腺肥大症治療における臨床効果の市場浸透と患者採用を強化するための実行可能な戦略的提言の策定

前立腺肥大症市場評価における調査結果の頑健性を保証する厳密なデータ収集分析および検証プロトコルの詳細

前立腺肥大症治療領域における将来の方向性と機会を明らかにするための主要知見と戦略的含意の統合

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場力学

第6章 市場洞察

第7章 米国の関税の累積的な影響2025

第8章 前立腺肥大症治療市場：治療タイプ別

第9章 前立腺肥大症治療市場：製品タイプ別

第10章 前立腺肥大症治療市場：エンドユーザー別

第11章 前立腺肥大症治療市場：流通チャネル別

第12章 南北アメリカの前立腺肥大症治療市場

第13章 欧州・中東・アフリカの前立腺肥大症治療市場

第14章 アジア太平洋地域の前立腺肥大症治療市場

第15章 競合情勢

第16章 リサーチAI

第17章 リサーチ統計

第18章 リサーチコンタクト

第19章 リサーチ記事

第20章 付録